Hennion & Walsh Asset Management Inc. Has $3.55 Million Stake in Phathom Pharmaceuticals, Inc. $PHATMarket Beat·Aug 11 at 04:13 AMPHAT+0.76%
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.5% - Here's WhyMarket Beat·Aug 4 at 12:00 PMPHAT+0.76%
17:34 ETPhathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)prnewswire·Jul 30 at 04:35 PMPHAT+0.76%
PHAT: VOQUEZNA drives GI market innovation with strong growth, clinical success, and extended exclusivityQuartr·Jul 30 at 06:21 AMPHAT+0.76%
Phathom Pharmaceuticals | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 74.27 MEarnings Watch·Jul 30 at 06:07 AMPHAT+0.76%
Phathom Q2 GAAP net loss narrows to $17.6 million from year-ago; revenue rises 88% to $74.3 millionPUBT·Jul 30 at 06:01 AMPHAT+0.76%
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) | PHAT Stock NewsStockTitan·Jun 22 at 10:59 PMPHAT+0.76%
